Last €0.0040 EUR
Change Today 0.00 / 0.00%
Volume 0.0
DU8 On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Frankfurt
As of 4:58 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

genetic technologies ltd (DU8) Snapshot

Open
€0.0050
Previous Close
€0.0040
Day High
€0.0050
Day Low
€0.0040
52 Week High
01/13/14 - €0.05
52 Week Low
10/6/14 - €0.0030
Market Cap
3.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
820.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENETIC TECHNOLOGIES LTD (DU8)

genetic technologies ltd (DU8) Related Bloomberg News

View More Bloomberg News

genetic technologies ltd (DU8) Related Businessweek News

No Related Businessweek News Found

genetic technologies ltd (DU8) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders. The company also provides DNA based tests comprising peace of mind paternity, legal paternity, antenatal DNA, deceased estate, DNA profiling, grandparent, immigration, sibling, twins, and Y-chromosome DNA tests. In addition, it offers DNA testing, canine health register, forensics, and breed identification services to animals. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited is headquartered in Fitzroy, Australia.

genetic technologies ltd (DU8) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$227.4K
Chief Financial Officer
Total Annual Compensation: A$14.4K
Director of Global Licensing & Intellectual P...
Total Annual Compensation: A$140.4K
Scientific Director
Total Annual Compensation: A$125.7K
Quality and Business Operations Director
Total Annual Compensation: A$98.7K
Compensation as of Fiscal Year 2014.

genetic technologies ltd (DU8) Key Developments

Genetic Technologies Limited Announces Executive Changes, Effective December 31, 2014

Genetic Technologies Limited announced key managerial appointments following the resignation of Ms. Alison Mew as Chief Executive Officer. Effective 31 December 2014, Ms. Alison Mew has decided to step down from her position of CEO, for personal, health-related reasons. The Board also announced that, following the resignation of Ms. Alison Mew, Mr. Eutillio Buccilli, the Company's current Chief Financial Officer, has been appointed to the position of Chief Operating Officer and Chief Financial Officer and that Mr. Mark Ostrowski, currently Senior VP Sales and Marketing, Phenogen Sciences Inc., based in the U.S., will assume the role of President, Phenogen Sciences Inc. Both new appointments become effective immediately. Mr. Buccilli joined the Company in June 2014, after more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with blue chip corporations such as General Electric, Computer Science Corporation, Coles Myer and Challenger Limited.

Genetic Technologies Limited, Annual General Meeting, Nov 25, 2014

Genetic Technologies Limited, Annual General Meeting, Nov 25, 2014., at 10:30 AUS Eastern Standard Time. Location: Treetops, Melbourne Museum. Agenda: To consider financial report, directors report and auditors report for the year ended June 30, 2014; to consider the election of directors; to consider the conversion of debt notes; to consider issue of options to debt note subscribers; to consider the renewal of employee option plan; and to consider the change of company name.

Genetic Technologies Limited Announces Quarterly BREVAGen(TM) Results

Molecular diagnostics (MDx) company Genetic Technologies Limited reported 942 BREVAGen(TM) test samples received in the September Quarter 2014, ahead of the release of the second generation breast cancer risk assessment test, BREVAGenplus(R), in October 2014. The September Quarter figure represents a slight increase over previous corresponding period, and was consistent with the average number of patient samples received during first quarter and second quarter of current year 2014. Market preparation for the release of the second generation test saw major breast centres and physicians holding off on ordering BREVAGen tests in anticipation of BREVAGenplus(R), scheduled release. The September Quarter also represents the traditional summer holiday vacation period in the US. On 1 October 2014, the Company announced the US launch of BREVAGenplus(R), an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The new test represents an enhancement of the first generation BREVAGen product. BREVAGenplus(R) utilises a 10-fold expanded SNP (Single Nucleotide Polymorphism) panel which incorporates the latest scientific developments obtained from association studies. It is directed primarily towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer or other potentially confounding pathology and have one or more risk factors for developing breast cancer. BREVAGenplus(R) assesses both clinical risk factors and genetic markers known to be associated with sporadic (non-hereditary) breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DU8:GR €0.00 EUR 0.00

DU8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $41.13 USD -0.24
Sonic Healthcare Ltd A$18.38 AUD -0.04
View Industry Companies
 

Industry Analysis

DU8

Industry Average

Valuation DU8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECHNOLOGIES LTD, please visit www.gtglabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.